THERAPEUTIC ANTIBODY DISCOVERY
When tasked with difficult therapeutic targets (cell surface, multispanning transmembrane proteins, glycoproteins, etc.) there are a few things that make Abveris uniquely equipped to deliver with the best chance of success. This includes our comprehensive services, immunization expertise, and access to leading discovery platforms.
Work at Abveris is industry-leading as well as milestone and royalty-free!
SERVICIOS COMPLETOS
FASE TEMPRANA
When working on unique targets, it may be difficult to find reliable reagents, namely proteins and/or cell lines. Our protein and cell line generation capabilities help to ensure that the appropriate amounts of immunization and screening materials are available. Once the project is complete, all remaining material are sent to our partners so that the materials can continue to be used as needed.
FASE INTERMEDIA: DESCUBRIMIENTO Y CRIBADO
El cribado de linfocitos B basado en Beacon y los procesos de desarrollo de hibridomas optimizados permiten el descubrimiento de grupos grandes y diversos de AcM.
Nuestro conjunto de plataformas de cribado y caracterización de alto rendimiento nos permite, no solo identificar ligantes ideales, sino también cribar anticuerpos funcionalmente relevantes y de alta afinidad en una fase temprana del proceso de descubrimiento. La citometría de flujo de alto rendimiento nos permite analizar la unión en las células, además de la actividad funcional.
FASE TARDÍA
Next-generation sequencing efforts are accompanied by custom data reports that highlight developability concerns and deliver more value. La producción de anticuerpos recombinantes proporciona a nuestros socios la opción de producir grandes cantidades de su anticuerpo elegido en una línea celular de mamíferos fiable.
EXPERIENCIA EN INMUNIZACIÓN
Abveris se enorgullece de su experiencia y de la variedad de funciones de inmunización que ofrece. Entre los métodos de inmunización, se incluyen los siguientes:
- Basados en péptidos y proteínas
- Basados en células
- Basados en células sustractivas
- Basados en ADN
- Basados en partículas similvíricas (VLP)
- Basados en rupturas de tolerancia
The hyperimmune response of the DiversimAb mouse can generate appropriate titers in as little as 3 weeks, enabling rapid antibody discovery. Los protocolos de inmunización patentados y adyuvantes patentados permiten a nuestro equipo explotar las funciones hiperinmunes y autoinmunes de nuestra cepa de ratones patentada para optar a mayores posibilidades de conjuntos de anticuerpos diversos y de reactividad cruzada. A través de nuestro trabajo con distintas plataformas de tipo humanizado, hemos optimizado nuestros métodos de inmunización para aplicarlos a los modelos de ratón que se suelen emplear para campañas de descubrimiento terapéutico.
PLATAFORMAS DE DESCUBRIMIENTO DESTACADAS
Abveris leverages a number of high throughput platforms for antibody screening and characterization. Entre estas plataformas, se incluyen los sistemas TECAN para ELISA de alto rendimiento, la citometría de flujo iQue para cribados celulares de alto rendimiento, la resonancia de plasmón de superficie (SPR) de Carterra y Octet para análisis de cinética de anticuerpos.
Our Toolbox
- Antigen and screening materials development
- Delivery of fully human mAbs using humanized mice from Alloy and Harbour
- Proprietary, hyper-immune DiversimAb mice to generate a more diverse mAb response than wild-type mice
- Multiple immunization techniques including: DNA immunization, cell immunization, rapid protocols, adjuvants to break tolerance and assist in cross-reactivity and more
- Highly efficient B cell screening (Beacon) and hybridoma approaches
- High-throughput, industry-leading screening tools to identify ideal mAbs including the iQue flow cytometer along with the Octet and Carterra systems for affinity, activity and epitope binning analysis.
- In-house sequencing capabilities
- Scale-up and purification of mAb from hybridoma or recombinantly
ANTI-IDIOTYPE ANTIBODY DISCOVERY
At Abveris, we deliver high-quality anti-idiotype antibodies using our DiversimAbTM platform. We apply stringent, high content screening in relevant formats predictive of downstream assay success to identify quality reagents for your specific drug development assays (e.g. PK and ADA).
- High-speed offerings
- 94% success-rate delivering on our partner's goals
- Stringent screening packages
- Diverse assay candidates delivered
Sabemos que estos AcM son herramientas esenciales para el desarrollo de ensayos clínicos y la velocidad con la que suministramos reactivos de alta calidad afecta en última instancia a la vida de los pacientes. Nuestro equipo se enorgullece del trabajo que llevamos a cabo y prioriza el suministro de anticuerpos de la máxima calidad en plazos líderes en el sector para respaldar sus ensayos clínicos.
CELL SURFACE TARGETING MABS
Our Secrets to Success
SELECT PROPER IMMUNOGENS
It is often challenging to present cell surface targets with proper conformation and post-translational modifications. Abveris applies innovative cell-based and DNA-based immunization protocols for cell surface immunogens to maintain the integrity of their complex structures. For certain targets and applications, recombinant proteins and peptide strategies may also provide value.
ABVERIS DIVERSIMAB™ TECHNOLOGY
The proprietary Abveris DiversimAb™ mouse provides the best in vivo option for generating monoclonal antibodies against membrane targets. DiversimAb™ technology can be applied to generate diverse panels of antibodies against tough targets, even when there are very few surface epitopes available. Abveris welcomes humanized mouse strains for fully human therapeutic antibody discovery, or knockout strains at the request of our partners.
HIGH-THROUGHPUT CELL BINDING ANALYSIS
The critical metric for success in antibody discovery for membrane targets is “on-cell binding,” thus necessitating frequent use of flow cytometry screening. The use of high-throughput flow cytometry technology unlocks the ability to screen massive panels of hybridomas with high resolution in hours instead of days.
REPERTOIRE MINING
Nature often has the superior power to utilize the diversity of immune repertoire to provide innovative insights into antibody engineering that rational design approaches may easily accomplish.
In conjunction with Abveris' proprietary hyperimmune mouse family (DievrsimAbTM Platform) and advanced screening technologies, the Hit Expansion Workflow offers opportunities to harness the power of natural repertoire diversity to expand the sequence space for rare, functionally-relevant hits, while increasing the success of antibody discovery against challenging therapeutic targets.
